86
Participants
Start Date
August 2, 2018
Primary Completion Date
July 22, 2021
Study Completion Date
September 12, 2023
Trastuzumab deruxtecan
The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
Nivolumab
Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
Cliniques Universitaires Saint-Luc, Brussels
GZA Hospital Campus Sint-Augustinus, Wilrijk
AZ Groeninge, Kortrijk
Icahn School of Medicine at Mount Sinai, New York
Charite Campus Benjamin Franklin, Berlin
Ospedale San Raffaele, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Centre Georges Francois Leclerc, Dijon
Hospital Gregorio Maranon Madrid Spain, Madrid
MD Anderson Cancer Center Madrid, Madrid
Hospital Universitario Ramon y Cajal Madrid, Madrid
Fundacion Jimenez Diaz, Madrid
START Madrid CIOCC, Madrid
Levine Cancer Institute Carolinas Healthcare System, Charlotte
University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center, Miami
Tennessee Oncology - Sara Cannon Research Institute, Nashville
Norton Cancer Institute, Louisville
Gabrail Cancer Center Research, Canton
ICO Rene Gauducheau, Saint-Herblain
Institut de Cancerologie de L'Ouest, Angers
Azienda Ospedaliera Universitaria Senese U.O.C. Immunoterapia Oncologica, Siena
University Hospital Frankfurt, Frankfurt am Main
Huntsman Cancer Institute, Salt Lake City
UCLA - Medical Center, Santa Monica
University of Washington Medical Center, Seattle
Yale University, New Haven
University Cancer Center, Dresden
Sarah Cannon Research Institute UK, London
Royal Marsden Hospital (Surrey), Sutton
Lead Sponsor
Collaborators (2)
Bristol-Myers Squibb
INDUSTRY
AstraZeneca
INDUSTRY
Daiichi Sankyo
INDUSTRY